TL;DR
- Knowledge graphs connect pharmaceutical entities such as drugs, genes, proteins, diseases, pathways, and clinical evidence.
- Their strongest research applications include drug-target discovery, drug repurposing, pharmacovigilance, and biological data interpretation.
- They help researchers explore relationships across fragmented datasets and generate hypotheses that may be difficult to identify through isolated database searches.
- Their usefulness depends on reliable source data, consistent identifiers, evidence provenance, and experimental or clinical validation.
Pharmaceutical research generates information across scientific publications, genomic databases, chemical repositories, laboratory experiments, clinical studies, and drug safety systems. Each source provides part of the picture, but understanding a drug or disease often requires connecting information across several of them.
For example, researchers investigating a therapeutic target may need to understand its associated genes, proteins, biological pathways, disease relationships, known compounds, and supporting experimental evidence.
A conventional database can store these records, but exploring relationships across multiple sources can require complex queries and manual analysis.
Knowledge graphs provide another way to organize this information. They represent scientific entities as connected nodes and their relationships as edges, creating a structure researchers can query and analyze.
For pharmaceutical companies, this approach has several important applications—from identifying potential drug targets to investigating adverse reactions and interpreting multi-omics data.
What Is a Knowledge Graph in Pharmaceutical Research?
A knowledge graph is a structured representation of entities and the relationships between them.
In pharmaceutical research, entities can include:
- Drugs: Approved medicines, investigational compounds, and chemical substances.
- Biological entities: Genes, proteins, enzymes, and molecular targets.
- Diseases: Conditions, phenotypes, and disease subtypes.
- Biological processes: Pathways, molecular interactions, and mechanisms.
- Research evidence: Publications, experiments, clinical trials, and reported outcomes.
Relationships describe how these entities connect. For example, a compound may inhibit a protein, the protein may participate in a biological pathway, and that pathway may be associated with a disease.
A knowledge graph can represent these connections in a single queryable structure.
This is different from simply collecting information in one database. The graph explicitly represents relationships, making it possible to explore multi-step connections between scientific concepts.
5 Best Applications of Knowledge Graphs for Pharma
1. Drug Target Identification and Discovery
Identifying promising drug targets is one of the most established applications of knowledge graphs in pharmaceutical research.
A potential target must be evaluated in the context of its biological function, disease association, molecular interactions, and supporting evidence.
Knowledge graphs can connect information from genomic databases, protein interaction networks, pathway repositories, chemical databases, and scientific publications.
How pharmaceutical researchers use them:
- Identify genes and proteins associated with a disease.
- Explore relationships between molecular targets and biological pathways.
- Find compounds known to interact with a particular target.
- Examine evidence connecting a target to a disease mechanism.
- Prioritize potential targets for further experimental investigation.
For example, researchers investigating a disease-associated protein can explore its interacting proteins, related pathways, known inhibitors, and published experimental findings.
These connections can help generate and prioritize hypotheses. They do not establish that a target is therapeutically effective; laboratory and subsequent clinical evidence are still required.
2. Drug Repurposing and Repositioning
Drug repurposing involves investigating whether an existing drug could be useful for a different disease or therapeutic indication.
This is a particularly relevant knowledge graph application because drugs, targets, genes, diseases, and pathways can be represented within the same network.
How pharmaceutical researchers use them:
- Connect existing drugs with molecular targets.
- Identify diseases associated with those targets.
- Explore shared biological pathways between different conditions.
- Investigate relationships reported in scientific literature.
- Prioritize potential drug-disease associations for further study.
For example, if an existing compound interacts with a protein involved in a different disease pathway, a knowledge graph may help researchers identify that connection and investigate whether it has therapeutic relevance.
Graph-based methods can also use link prediction to identify relationships that are not explicitly recorded in the existing graph.
A 2024 review in Briefings in Bioinformatics examined knowledge graph databases and methods used for drug repurposing. A 2025 scoping review further explored multi-relation learning approaches in this area.
The important limitation is that a predicted drug-disease relationship is a hypothesis, not evidence of clinical efficacy. Experimental testing, safety assessment, and clinical evaluation remain necessary.
3. Pharmacovigilance and Drug Safety
Pharmacovigilance involves identifying, assessing, and monitoring potential adverse effects associated with medicines.
Drug safety information can be distributed across adverse event reports, drug labels, scientific literature, clinical studies, and other databases. Knowledge graphs can connect these sources to support relationship analysis.
How pharmaceutical researchers use them:
- Connect drugs with reported adverse reactions.
- Explore relationships between drug targets and potential safety effects.
- Investigate possible drug-drug interactions.
- Identify relationships between patient characteristics and reported events.
- Support the prioritization of potential safety signals for review.
For example, researchers investigating a reported adverse event may explore whether other drugs acting on related targets or pathways have similar safety associations.
A 2024 scoping review in Clinical Therapeutics examined 47 peer-reviewed studies applying knowledge graphs to pharmacovigilance. The studies covered adverse drug reaction prediction and drug-drug interaction analysis.
However, reported performance varied, and comparisons with established pharmacovigilance methods were limited. Knowledge graphs should therefore support—not replace—established safety monitoring, signal assessment, and expert review.
4. Multi-Omics Integration and Biological Mechanism Analysis
Pharmaceutical research increasingly combines information from multiple biological measurement technologies.
Genomics, transcriptomics, proteomics, metabolomics, and other datasets provide different views of biological systems. Understanding how these layers interact can be difficult when the information is stored in separate formats and repositories.
Knowledge graphs can represent relationships across these biological layers.
How pharmaceutical researchers use them:
- Connect genes with their expressed proteins.
- Relate proteins to biological pathways.
- Explore pathways associated with disease phenotypes.
- Link molecular findings with experimental observations.
- Investigate potential biomarker relationships.
For example, a researcher studying a disease may connect gene-expression changes with protein interactions and relevant biological pathways to investigate a possible mechanism.
This can help organize complex research evidence and identify relationships worth investigating further.
The quality of these insights depends on consistent identifiers, reliable experimental data, appropriate biological context, and careful interpretation. A graph cannot compensate for incomplete or inaccurate source data.
5. Scientific Literature Mining and Research Intelligence
Pharmaceutical teams work with large volumes of scientific publications, patents, clinical trial records, and internal research documents.
Finding useful information often requires connecting findings across multiple sources rather than searching for individual keywords.
Knowledge graphs can help convert scientific information into structured entities and relationships.
How pharmaceutical researchers use them:
- Identify relationships between compounds, targets, and diseases in publications.
- Connect findings from different research papers.
- Explore evidence supporting a particular biological mechanism.
- Find related clinical studies and research areas.
- Support more contextual searches across scientific information.
Natural language processing can extract entities and relationships from scientific text, which can then be reviewed and incorporated into a knowledge graph.
Knowledge graphs can also support AI-powered research assistants. An AI system can interpret a research question and retrieve relevant graph relationships and supporting sources.
For example, a researcher investigating a particular protein could explore related diseases, known compounds, biological pathways, and publications through a connected search experience.
The graph can improve evidence retrieval and traceability, but extracted relationships and AI-generated answers still require source verification and scientific review.
How Pharmaceutical Companies Can Implement Knowledge Graphs
A knowledge graph should solve a defined research or business problem. Building a large graph without clear questions, reliable data, or an evaluation strategy can create additional complexity without delivering useful insights.
A practical implementation approach includes:
1. Start with a specific research question
Choose a focused use case, such as target identification, drug repurposing, or adverse event analysis.
Define the questions researchers should be able to answer and the evidence needed to support those answers.
2. Identify and connect relevant data sources
Determine which internal and external sources are required. These may include:
- Genomic and protein databases
- Chemical and compound repositories
- Scientific publications
- Clinical trial datasets
- Internal experimental results
- Drug safety information
The sources should be selected based on the use case rather than collected indiscriminately.
3. Standardize entities and relationships
Different databases may use different names or identifiers for the same gene, compound, disease, or protein.
Use consistent identifiers, controlled vocabularies, and appropriate ontologies to resolve these differences.
Define relationships clearly so that the graph represents meaningful scientific connections rather than superficial keyword associations.
4. Preserve evidence and data provenance
Record where each relationship came from, when it was collected, and how it was established.
A relationship extracted from a publication should not automatically be treated as equivalent to one supported by a validated experiment.
Provenance helps researchers evaluate the reliability and relevance of graph-based findings.
5. Evaluate and maintain the graph
Review data completeness, relationship accuracy, source quality, and the performance of analytical methods.
Update source information as scientific knowledge changes. Use domain experts to assess whether generated hypotheses are scientifically meaningful.
The Role of Connected Laboratory Data in Knowledge Graph Applications
Knowledge graphs can connect information from external scientific databases, but pharmaceutical companies also need to account for data generated inside their own laboratories.
Experimental results, sample metadata, assay information, instrument outputs, and analytical findings can provide valuable context for research knowledge systems.
The challenge is that this information often lives across separate LIMS, ELNs, instrument software, and data repositories.
Before laboratory information can contribute reliably to a knowledge graph, teams need consistent identifiers, structured metadata, clear data relationships, and dependable integration.
Scispot's Lab Operating System connects laboratory applications, instruments, data, and workflows through a governed data environment.
Its GLUE integration layer helps connect laboratory systems and move data across existing applications.
These capabilities can support the data foundation needed for broader research data and AI initiatives. They should not be confused with a claim that Scispot provides a native pharmaceutical knowledge graph or drug-discovery prediction engine.
For pharmaceutical teams, the practical starting point is to make laboratory data more structured, connected, and accessible before building advanced knowledge-driven applications.
Build a Stronger Data Foundation for Pharmaceutical Research
Knowledge graphs can help pharmaceutical teams connect scientific information and explore relationships across complex datasets. But their usefulness depends on the quality, structure, and context of the underlying data.
Scispot helps laboratories connect instruments, applications, and research workflows through a unified Lab Operating System.
Bring your lab data, instruments, and workflows together with Scispot.
